CHEK2 and hereditary cancer: This is a well-known issue in the field of hereditary cancer, where the indication and effect of surveillance programs are controversial ‒ to name a few: CHEK2 and ATM. Although some guidelines have proposed surveillance in families that carry a LPV/PV in RNF43, there is a definite risk of overtreatment [16].